eli lilly glp-1 supply news today Lilly's outdoes Novo Nordisk's in trial GLP-1 demand boom continues as

Pre-clinical studies have demonstrated mixed findings, including potential protective effects of GLP-1 RAs in the context of diabetic retinopathy, with GLP-1 receptors found in the RPE serving a neuroprotective role in conditions of high glucose

10.1111/J.1471-4159.2010.07168.X 135 SadakaA

Gonzalez-Ortiz et al., 2008[20]

Akiska et al

Safety considerations specific to these blends include copper accumulation risk with elevated GHK-Cu dosing, the pro-angiogenic activity of GHK-Cu and TB-500 that warrants caution in individuals with oncologic history, and the very short half-life of KPV (approximately 15 minutes) which limits its systemic bioavailability without advanced delivery strategies like PEGylation or liposomal encapsulation